Maryland Heights, MO, June 25, 2016 --(PR.com
)-- According to a market research report published by iHealthcareAnalyst, Inc., Smoking Cessation and Nicotine De-Addiction Products Market – Global Nicotine Replacement Therapy Products Analysis and Forecast 2013-2020, the global smoking cessation and nicotine de-addiction products market was valued at USD 6.8 Billion in 2015 and is estimated to reach USD 14.5 Billion by 2020, at a CAGR of 16.4% from 2016 to 2020.
Browse the Smoking Cessation and Nicotine De-Addiction Products Market – Global Nicotine Replacement Therapy Products Analysis and Forecast 2013-2020 at http://www.ihealthcareanalyst.com/report/smoking-cessation-nicotine-de-addiction-products-market/
Nicotine is addictive, and quitting smoking leads to symptoms of nicotine withdrawal such as craving, anxiety and irritability, depression, and weight gain. Professional smoking cessation support methods generally endeavor to address both nicotine addiction and nicotine withdrawal symptoms. Interventions such as nicotine replacement therapies (NRTs) work by delivering nicotine into the body to ease withdrawal while allowing the smoker to break the behavioral habits associated with the cigarette itself. The antidepressant bupropion is considered a first-line medication for smoking cessation and has been shown in many studies to increase long-term success rates. Varenicline decreases the urge to smoke and reduces withdrawal symptoms and is therefore considered a first-line medication for smoking cessation. Clonidine may reduce withdrawal symptoms and "approximately doubles abstinence rates when compared to a placebo," but its side effects include dry mouth and sedation, and abruptly stopping the drug can cause high blood pressure and other side effects. The global smoking cessation and nicotine de-addiction products market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the product types (nicotine replacement therapy products - nicotine gums, nicotine inhalers, nicotine lozenges, nicotine sprays, nicotine sublingual tablets, nicotine transdermal patches; drug therapy - Chantix or champix, zyban; and e-cigarettes), and forecasts growth trends (CAGR% - 2015 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends.
The global smoking cessation and nicotine de-addiction products market is segmented as:
1. Product Type
1.1. Nicotine Replacement Therapy (NRT) Products
1.1.1. Nicotine Gums
1.1.2. Nicotine Inhalers
1.1.3. Nicotine Lozenges
1.1.4. Nicotine Sprays
1.1.5.Nicotine Sublingual Tablets
1.1.6. Nicotine Transdermal Patches
1.2. Drug Therapy
1.2.1. Chantix or Champix (varenicline)
1.2.2. Zyban (bupropion)
2. Geography (Region, Country)
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World
3. Company Profiles
4. Cipla Ltd.
5. GlaxoSmithKline plc
6. Imperial Tobacco Company of India Limited.
7. McNeil AB
8. NJOY, Inc.
9. Novartis AG
10. Pfizer, Inc.
11. Revolymer PLC
12. Takeda Pharmaceutical Co., Ltd.
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043